| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
A DNA and/or RNA-alkylating damage-repair enzyme called prostate cancer antigen (PCA)-1 is highly expressed in clinical androgen-independent prostate cancer cells and pancreatic cancer cells. Genetic inhibition of the enzymatic activity by injecting siRNA effectively inhibited the growth of prostate and pancreatic cancer cells. Therefore, PCA-1 inhibitor would be a novel and clinically effective anti-cancer drug against prostate cancer, even for hormone independent varieties and pancreatic cancer.
On the other hand, on the guidance of inhibition against PCA-1 enzymatic activity, we tried to search for anti-cancer substances from extracts of medicinal plants. We found several active extract and isolate the active components by the assay-guided separation.
|
